Remove B2C Remove Compliance Remove Concentration
article thumbnail

Transcript: David Roux, BayPine, Silver Lake Partners

Barry Ritholtz

00:16:27 [Speaker Changed] How much of what’s been going on in the 2020s has been a focus on that same top 10% of tech companies as being overly concentrated and wildly expensive. The parallels are that there is a concentration of interest. ’cause it had been very much a kind of B2C phenomenon, right?

article thumbnail

Transcript: Annie Lamont, Oak HC/FT

Barry Ritholtz

So if you can manage drug compliance better, and most importantly, the easiest but not easy thing to do is to keep people out of the hospital appropriately. 00:44:44 [Speaker Changed] Ju literally just had this conversation yesterday with my head of compliance. And drug costs. Nobody wants to be at a hospital.